Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer

NCT07593976 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

OTHER: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography

Sponsor

Centre Henri Becquerel